Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 162
- Registration Number
- NCT06689241
- Locations
- 🇪🇬
Alexandria University, Alexandria, Egypt
Dabigatran for the Adjunctive Treatment of Staphylococcus Aureus Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Emily McDonald
- Target Recruit Count
- 300
- Registration Number
- NCT06650501
- Locations
- 🇨🇦
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec, Canada
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- VarmX B.V.
- Target Recruit Count
- 16
- Registration Number
- NCT06517563
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06476301
The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 324
- Registration Number
- NCT06449469
- Locations
- 🇩🇰
Aarhus University Hospital, Skejby, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06444178
- Locations
- 🇬🇧
Fortrea Clinical Development, Leeds, United Kingdom
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population
- Conditions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 20
- Registration Number
- NCT06371170
- Locations
- 🇮🇹
CCPC, Ancona, Marche, Italy
Thromboprophylaxis in Lower Limb Immobilisation
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 10044
- Registration Number
- NCT06370273
- Locations
- 🇬🇧
Epsom and St Helier University Hospitals NHS Trust, Carshalton, Surrey, United Kingdom
🇬🇧Barts Health NHS Trust, London, United Kingdom
🇬🇧Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom
The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06362343
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT06216769
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.